Full history for every metric is available with a Kvantra account
Acelyrin, Inc. (SLRN)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -316 | -293 | |||||
| Net profit | $m | - | - | -42 | -250 | -382 | -248 | -269 |
| EPS reported | $ | -2.50 | -2.70 | |||||
| Operating cashflow per share | $ | -3.06 | -3.06 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -3.07 | -3.07 | |||||
| Free cash flow | $m | -305 | -287 | |||||
| Net debt | $m | -448 | -411 | |||||
| Book value equity | $m | 458 | 407 | |||||
| Book value per share | $ | 4.62 | 4.04 | |||||
| Number of shares | m | 99.3 | 100.68 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.68 | 0.56 | |||||
| P/S LTM | x | 0.00 | 670.07 | |||||
| P/FCF LTM | x | -1.02 | -0.80 | |||||
| EV/EBITDA LTM | x | -0.99 | 0.81 | |||||
| EV/Sales LTM | x | 0.00 | -530.49 | |||||
| Earnings Yield LTM | % | -79.61% | -110.12% | |||||
| FCF Yield | % | -97.87% | -125.14% | |||||
| Quality | ||||||||
| ROE | % | -54.16% | -44.54% | |||||
| ROIC | % | -68.08% | -68.08% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | +106.02% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -48.67 | -48.04 | |||||
| Net Debt/EBITDA | x | 0.27 | 0.27 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -143.64% | -179.17% | |||||
| Net debt/Equity | x | -0.98 | -1.01 | |||||
| Gross debt/equity | x | 0.01 | 0.01 | |||||
Company overview
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Acelyrin, Inc. (SLRN)
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free